Business & Finance

GVAX maker reports net loss of $26.0 million for the quarter

Published in Vaccine Weekly, August 25th, 2004

Cell Genesys, Inc., (CEGE) reported a net loss of $26.0 million, or $0.58 per share, for the quarter ended June 30, 2004.

This compares with a net loss of $19.1 million, or $0.51 per share, in the same quarter of 2003. Cell Genesys ended the quarter with approximately $173.7 million in cash, cash equivalents, and short-term investments, including restricted cash and investments, and in addition, held approximately 6.6 million shares of its former subsidiary, Abgenix, Inc.

Revenues for the quarter ended June 30, 2004 were $2.5 million compared with revenues of less than $0.1 million recognized for the comparable period in 2003, an increase reflecting...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-08-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry